The cost-effectiveness of different management strategies for patients on chronic warfarin therapy
OBJECTIVE: To examine the cost-effectiveness of moving from usual care to more organized management strategies for patients on chronic warfarin therapy.
DESIGN: Using information available in the scientific literature, supplemented with data from a large health system and, when necessary, expert opinion, we constructed a 5-year Markov model to evaluate the health and economic outcomes associated with each of three different anticoagulation management approaches: usual care, anticoagulation clinic testing with a capillary monitor, and patient self-testing with a capillary monitor.
PATIENTS: Three hypothetical cohorts of patients beginning long-term warfarin therapy were used to generate model results.
MAIN RESULTS: Model results indicated that moving from usual care to anticoagulation clinic testing would result in a total of 1.7 thromboembolic events and 2.0 hemorrhagic events avoided per 100 patients over 5 years. Another 4.0 thromboembolic events and 0.8 hemorrhagic events would be avoided by moving to patient self-testing. When direct medical care costs and those incurred by patients and their caregivers in receiving care were considered, patient self-testing was the most cost-effective alternative, resulting in an overall cost saving.
CONCLUSIONS: Results illustrate the potential health and economic benefits of organized care management approaches and capillary monitors in the management of patients receiving warfarin therapy.
Key Wordsanticoagulation management cost-effectiveness analysis decision analytic model warfarin
Unable to display preview. Download preview PDF.
- 3.Chiquette E, Amato MG, Bussey HI. Comparison of an anticoagulation clinic with routine medical care. Circulation. 1995;92:1–686. Abstract.Google Scholar
- 7.Hasenkam JM, Knudsen L, Kimose HH, et al. Practicability of patient self-testing or oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor. A pilot investigation. Thromb Res. 1997;85:77–82.Google Scholar
- 8.Bernardo A, Halhuber C. Long-term experience with patient self-management of oral anticoagulation. Ann Hematol. 1996;72:A62. Abstract.Google Scholar
- 15.European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1255–62.Google Scholar
- 18.Petersen P, Godtfredsen J, Boysen G, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;175–8.Google Scholar
- 19.Stroke Prevention in Atrial Fibrillation Investigators. Stroke prevention in atrial fibrillation study. Circulation. 1991;84:527–39.Google Scholar
- 20.Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study. Lancet. 1994;343:687–91.Google Scholar
- 34.Sarent R, Wainwright E. Crystal Ball Version 4.0 User Manual. Broomfield, Colo: CG Press; 1996.Google Scholar
- 35.Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press, Inc, 1996.Google Scholar
- 37.US Bureau of the Census, Current Population Reports, Money Income in the United States: 1996 (With Separate Data on Valuation of Noncash Benefits). Washington, DC: US Government Printing Office; 1997:60–197, Table 7.Google Scholar
- 40.Holloway RG, Witter DM, Lawton KB, Lipscomb J, Samsa G. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology. 1996;46:860.Google Scholar
- 41.Health Insurance Association of America. Washington, DC: Source Book of Health Insurance Data, 1996. 854–60:1997.Google Scholar